Search Within

Anas Younes

  1. "Department of Medicine"
Formats
  1. Meeting Abstract (152)
  2. Journal Article (136)
  3. Book Section (13)
  4. Book Whole (4)
  5. Editorial (4)
  6. Review (4)
  7. Conference Paper (2)
  8. Research Letter (2)
  9. Correspondence (1)
  10. Miscellaneous (1)
Groups
  1. Center for Hematologic Malignancies (319)
  2. Department of Medicine (319)
  3. Executive Committee, Center for Hematologic Malignancies (319)
  4. Hematologic Malignancies, Division of (319)
  5. Lymphoma (319)
  6. Epidemiology and Biostatistics (82)

More Groups

People
  1. Andrew Zelenetz (88)
  2. Connie Batlevi (81)
  3. David Straus (73)
  4. Matthew Matasar (68)
  5. Anita Kumar (66)
  6. Paul Hamlin (66)

More People

Years
  1. 2024 (2)
  2. 2023 (7)
  3. 2022 (11)
  4. 2021 (13)
  5. 2020 (26)
  6. 2019 (53)

More Years

Publications
  1. Blood (90)
  2. Journal of Clinical Oncology (25)
  3. Hematological Oncology (22)
  4. Haematologica (16)
  5. British Journal of Haematology (13)
  6. Cancer Research (10)

More Publications

Publishers
  1. American Society of Hematology (98)
  2. American Society of Clinical Oncology (27)
  3. Wiley Blackwell (25)
  4. Nature Publishing Group (19)
  5. Springer (17)
  6. American Association for Cancer Research (16)

More Publishers

Results (319)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • MSK-IMPACT Heme: Validation and clinical experience of a comprehensive molecular profiling platform for hematologic malignancies
    Meeting Abstract

    Ptashkin, R. N.; Benayed, R.; Ziegler, J.; Rema, A. B.; Sadowska, J.; Kiecka, I.; Ho, C.; Yao, J. J.; Moung, C.; Petrova-Drus, K.; more...
    Cancer Research (2019)

    Fulltext@MSK | Save
  • Phase 1/2a LYM1002 study of ibrutinib (ibr) + nivolumab (nivo): Exome and gene expression profiling (GEP) analyses by histology and responder status
    Meeting Abstract

    Hodkinson, B.; Schaffer, M.; Brody, J.; Jurczak, W.; Carpio, C.; Ben-Yehuda, D.; Avivi, I.; Saleem, R.; Ozcan, M.; Alvarez, J.; more...
    Cancer Research (2019)

    Fulltext@MSK | Save
  • Lymphocyte-to-monocyte ratio may serve as a better prognostic indicator than tumor-associated macrophages in DLBCL treated with rituximab
    Journal Article

    Matsuki, E.; Bohn, O. L.; El Jamal, S.; Pichardo, J. D.; Zelenetz, A. D.; Younes, A.; Teruya-Feldstein, J.
    Applied Immunohistochemistry & Molecular Morphology (2019)

    Fulltext@MSK | Save
  • Reply to M. Skelin et al
    Correspondence

    Wilson, W. H.; Staudt, L.; Younes, A.
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Phase 1 study of CA-4948, a novel inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4) in patients with R/R non-Hodgkin lymphoma (NHL)
    Meeting Abstract

    Younes, A.; Nowakowski, G.; Rosenthal, A.; Leslie, L.; Tun, H.; Lunning, M.; Isufi, I.; Martell, R.; Patel, K.
    Clinical Lymphoma, Myeloma and Leukemia (2019)

    Fulltext@MSK | Save
  • Will GALEN become more RELEVANT?
    Editorial

    von Keudell, G.; Younes, A.
    The Lancet Haematology (2019)

    Fulltext@MSK | Save
  • Noncovalent inhibitors reveal BTK gatekeeper and auto-inhibitory residues that control its transforming activity
    Journal Article

    Wang, S.; Mondal, S.; Zhao, C.; Berishaj, M.; Ghanakota, P.; Batlevi, C. L.; Dogan, A.; Seshan, V. E.; Abel, R.; Green, M. R.; more...
    JCI Insight (2019)

    Fulltext@MSK | Save
  • Emerging epigenetic-modulating therapies in lymphoma
    Review

    Sermer, D.; Pasqualucci, L.; Wendel, H. G.; Melnick, A.; Younes, A.
    Nature Reviews Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Resource utilization within 30 days of car T cells for hematologic malignancies
    Meeting Abstract

    Shah, G.; Park, J.; Sauter, C.; Duck, E.; Halton, E.; Batlevi, C.; Palomba, M. L.; Younes, A.; Geyer, M.; Smith, E.; more...
    Value in Health (2019)

    Fulltext@MSK | Save
  • Dose finding study to assess safety, PK and efficacy of fimepinostat (CUDC‐907) with venetoclax or rituximab plus bendamustine in patients with relapsed/refractory lymphoma
    Meeting Abstract

    Younes, A.; Batlevi, C. L.; Cohen, J. B.; Kelly, K.; Landsburg, D. J.; Patel, K.; Phillips, T.; Smith, S.; Westin, J.; Ma, A. W.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save